Periodic Reporting for period 1 - PEPTO1 (Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy)

Peptomyc S.L. is a spin-off company created at the Vall d’Hebron Institute of Oncology (VHIO) to develop a new, first-in-class, cancer therapy based on the use of innovative anti-Myc peptides. Myc is an oncogene deregulated in the majority of human cancers, making...